Clinical data | |
---|---|
Trade names | Fasinex, Egaten, others |
AHFS/Drugs.com | International Drug Names |
Routes of administration |
by mouth |
ATC code | |
Pharmacokinetic data | |
Metabolism | Oxidation to the sulfone and sulfoxide parent compound |
Biological half-life | 22–24 hs |
Excretion | Feces (>95%), urine (2%), milk (<1%) |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.127.414 |
Chemical and physical data | |
Formula | C14H9Cl3N2OS |
Molar mass | 359.658 |
3D model (Jmol) | |
|
|
|
|
(what is this?) |
Triclabendazole, sold under the brand name Egaten among others, is a medication used to treat liver flukes, specifically fascioliasis and paragonimiasis. It is very effective for both conditions. Treatment in hospital may be required. It is taken by mouth with typically one or two doses being required.
Side effects are generally few, but can include abdominal pain and headaches.Biliary colic may occur due to dying worms. While no harms have been found with use during pregnancy, triclabendazole has not been well studied in this population. It is a member of the benzimidazole family of medications for worms.
It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is not commercially available in the United States. For human use it can be gotten from the World Health Organization. It is also used in other animals.
It is a member of the benzimidazole family of anthelmintics. The benzimidazole drugs share a common molecular structure, triclabendazole being the exception in having a chlorinated benzene ring but no carbamate group. Benzimidazoles such as triclabendazole are generally accepted to bind to beta-tubulin and prevent the polymerization of the microtubules of which they are part.
Since late 1990s, triclabendazole became available as a generic drug, as patents expired in many countries. Many products were developed then. Among them, Trivantel 15, a 15% triclabendazole suspension, was launched by Agrovet Market Animal Health in the early 2000s. In 2009, the first triclabendazole injectable solution (combined with ivermectin) was developed and launched, also by Agrovet Market Animal Health. The product, Fasiject Plus, a triclabendazole 36% and ivermectin 0.6% solution, is designed to treat infections by Fasciola hepatica (both immature and adult liver flukes), roundworms and ectoparasites, as well.